Company intelligence / Profile preview

Purine Pharmaceuticals

Gillette, New Jersey, USA

Ownership: Private
Development stage: Other

Overview

Purine Pharmaceuticals was spun out of Rutgers University and is developing a small molecule therapy for sepsis; current clinical results have not been publicly disclosed but company activity is limited to R&D and grant funding at the pre-clinical stage

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Rutgers University (academic spin-out)

Beyond the preview

Go deeper on Purine Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Purine Pharmaceuticals.

Explore the full profile